Annual Scientific Retreat Agenda


Tinkham Veale University Center 
11038 Bellflower Rd, Cleveland, OH 44106     

2:30 – 4:30 PM

Networking and Poster Sessions 

All poster session participants must stand by poster until judged

4:30 – 5:00     

Year of Accomplishments

Stan Gerson, MD
Director, Case Comprehensive Cancer Center 

5:00 – 6:00

TED-style Talks

Brian Bolwell, MD
Deputy Director for Cleveland Clinic, Case Comprehensive Cancer Center
Member, Hematopoietic and Immune Cancer Biology Program, Case Comprehensive Cancer Center

Peter Pronovost, MD, PhD, FCCM
Chief Clinical Transformation Officer
University Hospitals

Mark Griswold, PhD
Professor, Radiology
Member, Cancer Imaging Program, Case Comprehensive Cancer Center

6:00 – 6:15 

Poster Session Awards

6:15 – 7:30

Poster Session and Reception

Cocktails and heavy hors-d'oeuvres


Corporate College East   
4400 Richmond Rd, Cleveland, OH 44128

7:45 AM Breakfast and Registration Opens   
8:10 – 8:40

Strategic Directions
Stan Gerson, MD
Director, Case Comprehensive Cancer Center

8:40 – 9:00 

Trainee Platform Presentations

Alyssa Flynn
Graduate Student, Schiemann Lab, Department of Pharmacology

Salma Ben-Salem
Post-doc, Heemers Lab, Cleveland Clinic

9:00 – 10:00

Keynote Address

"P120catenin, EMT-MET plasticity and metastatic pancreatic cancer"
Anil Rustgi, MD
Director, Herbert Irving Comprehensive Cancer Center
Columbia University Irving Medical Center

10:00 – 10:15 Break
10:15 – 11:25 

Session I: Cancer Prevention and Population Health
Moderator: Monica Webb Hooper, PhD       

"What is our catchment area and how can we study it?"
Monica Webb Hooper, PhD

"Out of sync: circadian rhythm disruption and prostate cancer risk and progression"
Sarah Markt, ScD, MPH

"Prostate cancer risk stratification and genetic risk scores"
Fred Schumacher, PhD, MPH

"The APP-led Cancer Rehabilitation and Survivorship (ACReS) Program: improving transitions after cancer therapies to optimize outcomes in survivorship"
Kristine Zanotti, MD

Q & A

11:25 – 12:20 PM

Session II: Radiomics and Genomics in the Era of Precision Medicine
Moderator: Vinay Varadan, PhD

"New Computational Precision Medicine Approaches for Oncology"
Satish Viswanath, PhD

"Precision Medicine is Bayesian Exchangeability"
Brian Hobbs, PhD

"Artificial Intelligence in cancer research, the Case CCC Way"
Aziz Nazha, MD

Q & A

12:20 – 2:00

Lunch/Programs – Breakout rooms

  • Cancer Prevention, Control & Population Research (CPC) - Rm 229
  • Cancer Imaging(CI) - Rm 230
  • Developmental Therapeutics (DT) - Rm 234
  • GU Malignancies (GU) - Rm 207
  • GI Cancer Genetics (GICG) - Rm 208
  • Hematopoietic & Immune Cancer Biology (HICB) - Rm 203
  • Molecular Oncology (MO) - Rm 233

Trainee Session – Rm 205

  • Funding Resources
  • Career Trajectory/skillset
  • Skills Development/tool kit
  • Mentoring/Networking
  • Cancer Center Training Initiatives
2:00 – 2:55 Session III: Epigenomics and Gene Regulation
Moderator: Ahmad Khalil, PhD

"Dysregulation of lincRNAs impacts cancer progression and alters the epigenome"
Ahmad Khalil, PhD

"Insights into adult myeloid malignancies from pediatric inherited bone marrow failure syndromes: a fish tale"
Seth Corey, MD, MPH

"Exploiting dioxygenase dysfunction to target cancer"
Abhishek Chakraborty, PhD

Q & A

2:55 – 3:25

Shared Resources

Johnie Rose, MD, PhD

Imaging Research
Chris Flask, PhD

Cytometry & Microscopy
Judith Drazba, PhD

3:25 – 3:40 Break
3:40 – 4:20

Session IV: Cancer-Associated Syndromes and Metabolism
Moderator: Jennifer Dorth, MD

"Improving prediction of cancer-associated thrombosis: identifying candidate biomarkers"
Alok Khorana, MD

"Hydrogen sulfide as a diet-modifiable signaling metabolite and tumor suppressor"
Chris Hine, PhD

Q & A

4:20 – 5:15

Session V: Basic and Translational Cancer Biology
Moderator: Hannelore Heemers, PhD

"Pharmacologic inhibition of ezrin is a novel therapeutic strategy in rhabdomyosarcoma"
Neetu Gupta, PhD

"Diverse strategies of targeting telomerase with small molecules"
Derek Taylor, PhD

"Optimizing chemotherapeutic response using intentional hyperglycemia: implications for pancreatic cancer patients"
Jordan Winter, MD

Q & A

5:15 – 5:20 Wrap Up/Closing Comments
5:20 – 5:50

Executive Committee and Program Leaders Discussion (Closed Session)